EUCTR2020-001707-16-ES进行中（未招募）1 期
PHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMONIA AND BAD EVOLUTION - TOCICOVID
IIS BIODONOSTIA0 个研究点目标入组 60 人开始时间: 2020年7月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient over 18 years old
- •2) Ability to grant consent
- •3) Bilateral pneumonia caused by SARS-CoV-2 without response to the treatment used according to local protocol. This is defined as persistence of fever (above 37.5ºC without other focus) and respiratory worsening (more dyspnea, more cough, oxygen therapy at increasing doses, worsening of the degree of respiratory distress according to the PaO2 / FiO2 ratio in categories mild, moderate or serious ) or absence of improvement with respect to the previous state
- •4) Persistently elevated inflammatory markers, among which must be met: ferritin greater than 1000 ng / mL and / or D-dimer greater than 1500 ng / mL and / or IL-6 greater than 40 pg / mL [35-37].
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1) Pregnancy and lactation
- •2) Terminal situation or life expectancy less than 30 days in the judgment of the researcher
- •3) Allergy or intolerance to any of the drugs under study or to any of the excipients of the preparations (eg polysorbate 80)
- •4) Non-tolerable interaction of the study drugs with some essential chronic medication of the patient
- •5) Transaminases raised above five times the upper limit of normal
- •6) Severe neutropenia (<500 cells / mm3)
- •7) Plateletpenia <50,000 / mm3
- •8) Sepsis (clinical suspicion of active infection at another level with a value on the qSOFA scale of two or more points) or septic shock (need for vasopressors to maintain a mean arterial pressure greater than or equal to 65
- •mmHg, with a lactate greater than 2 mmol / L, despite adequate volume replacement
- •9) Another active infection at any level
- •10) Complicated diverticulitis or intestinal perforation
- •11) Kidney failure with estimated glomerular filtration less than 30 mL / min
- •12) Liver failure (Child B onwards)
- •13) Previous use (during the acute process or as chronic medication for another reason) of medication with potential effect in this phase of the disease (Janus kinase inhibitors, interleukin-1 inhibitors, other immunosuppressants or immunomodulators that, in the investigator's judgment) could have an effect on the disease based on pathophysiological criteria or previous research or started up in this same period)
- •14) Be included in another clinical trial
- •15) Patients who, due to their current situation, their baseline situation or other aspects, in the opinion of the researcher, are not considered candidates to enter the study
研究者
相似试验
进行中（未招募）
1 期
Randomized, multicenter, open, controlled clinical trial, to demonstrate the non-inferiority of reduced antibiotic treatment against the treatment of a broad spectrum in treating patients with bacteremia due to enterobacter.EUCTR2015-004219-19-ESFISEVI344
招募中
1 期
CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY IN ELDERLY PATIENTS WITH PERTROCHANTERIC FRACTURE, RECEIVING TREATMENT WITH TRANEXAMIC ACID IV VS IV+LOCAL IN THE SURGICAL BED.pertrochanteric hip fractureMedDRA version: 23.0Level: PTClassification code 10020100Term: Hip fractureSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2022-003163-21-ESCoral Sánchez Pérez102
已完成
3 期
A STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF BBIL?s TYPHOID Vi CAPSULAR POLYSACCHARIDE-TETANUS TOXOID PROTEIN CONJUGATE VACCINE VS REFERENCE VACCINE IN HEALTHY SUBJECTS.CTRI/2011/08/001957Bharat Biotech International Ltd981
已完成
4 期
A Study to Evaluate the Immunogenicity and Safety Of Booster Dose Effect BBIL Typhoid conjugate vaccineCTRI/2014/01/004341Bharat Biotech International Ltd981
已完成
不适用
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And VomitingPER-076-06GLAXOSMITHKLINE PERU S.A.,